A phase 1, randomized, placebo-controlled study to evaluate the safety and immunogenicity of an mRNA-based RSV prefusion F protein vaccine in healthy younger and older adults

• Published in: Human vaccines & immunotherapeutics Vol. 17; no. 5; pp. 1248 - 1261
• Main Authors: Aliprantis, Antonios O., Shaw, Christine A., Griffin, Paul, Farinola, Nicholas, Railkar, Radha A., Cao, Xin, Liu, Wen, Sachs, Jeffrey R., Swenson, Christine J., Lee, Heather, Cox, Kara S., Spellman, Daniel S., Winstead, Colleen J., Smolenov, Igor, Lai, Eseng, Zaks, Tal, Espeseth, Amy S., Panther, Lori
• Format: Journal Article
• Language: English
• Published: United States Taylor & Francis 04.05.2021; Taylor & Francis Group
• Subjects: prefusion F; Research Paper; Respiratory Syncytial Virus; RSV; vaccine; vaccine safety and immunogenicity; prefusion F; vaccine safety and immunogenicity; vaccine; Respiratory Syncytial Virus; RSV

Respiratory Syncytial Virus (RSV) causes lower respiratory tract infections that can be severe and sometimes fatal. The risk for severe RSV infection is highest in infants and older adults. A safe and effective RSV vaccine for older adults represents a serious unmet medical need due to higher morbid...